|Day Low/High||137.68 / 138.96|
|52 Wk Low/High||118.62 / 148.99|
These 'recession-resistant' names have proven they can thrive in a variety of economic conditions and through changing technologies and sentiments.
Johnson & Johnson is among the companies that Jim Cramer has put on his new GLOOM index.
Taking the measure of what's keeping the markets in the dumps.
The latest announcement from the U.S. Trade Representative's office is chilling reading for free trade supporters.
Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.
Tech and retail gains aren't enough to lead markets to new highs.
JNJ is one of the best of breed of the pharmaceuticals sector.
Johnson & Johnson is a premiere company, but the trick is knowing when to buy it.
Shares of the healthcare giant pick up a quant rating upgrade as the charts suggest gains ahead.
The potential of these setups on the weekly chart is rather good.
What's really surprising is the emergence of so many household names on the list.
The Nasdaq U.S. Broad Dividend Achievers Index is a good place to start.
Stock markets ran higher as investors turned towards domestic-focused companies.
It's hard to watch the market fall. But knowing you're still getting paid while it happens can make it much more palpable. That's why you need to have some dividend-producing stocks in your portfolio. Watch our video to find out why!
Markets were able to close the day in the green after a volatile day of trading.
The theft of intellectual property can be confronted by a Section 301 challenge directly from the trade representative.
Merger news, healthcare gains, industrials and even airlines joined the party.
With JNJ now set to close above $134, another look is in order.
We have a different kind of market where you must know the SYMBOLS and know what the companies do that are the symbols.
We could be poised for even a further advance PROVIDED that we stay oversold.
How do the charts look now and is it safe to consider being a buyer again?
There is nothing wrong with Intel, Johnson & Johnson, 3M and Apple.
With JPMorgan, Berkshire Hathaway and Amazon disrupting the health care space this morning a fresh look at JNJ is in order.
It's hard to understand the magnitude of the change.